Compare Wendys Co (WEN) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wendys Co vs Zimmer Biomet Holdings Inc — how do they compare? Wendys Co trades at $7.63 (market cap $1.50B), while Zimmer Biomet Holdings Inc trades at $90.03 (market cap $17.36B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 11.6× Wendys Co's market cap, and Wendys Co pays the higher dividend (7.13%). Which is the better fit depends on your goals.
| WEN | ZBH | |
|---|---|---|
Market Cap | $1.50B | $17.36B |
Sector | Consumer Cyclical | Health |
52-Week High | $11.33 | $107.71 |
52-Week Low | $6.17 | $79.58 |
Enterprise Value | $5.31B | $24.40B |
Dividend Yield | 7.13% | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Wendy's (WEN) trades at $7.63, down 1.68% on the day, with a bullish technical signal from moving averages and recent meme stock momentum. The company shows consistent earnings beats but faces margin pressure, with net income declining from $204M in 2023 to $165M in 2025. Valuation metrics appear attractive with a P/E of 10.2 and P/S of 0.69, while analyst consensus is mixed with a $7.96 price target.
The stock presents a value opportunity with solid dividends and low valuation, but investors face risks from declining profitability, high debt levels, and competitive pressures. Near-term catalysts include Q2 2026 earnings on August 7 and ongoing Project Fresh initiatives, though weak traffic and cost inflation remain headwinds for sustained growth.
Zimmer Biomet (ZBH) trades at $88.92, down 2.41% on the day, with a bearish technical signal but strong fundamentals including a 70.03% gross margin and three consecutive quarterly EPS beats. Revenue grew to $8.23B in 2025, though net income margin compressed to 8.56%. The company announced a $1 billion share repurchase increase and expansion in India, while maintaining a dividend.
The stock offers a 10% upside to the $97.67 consensus price target, supported by value metrics and operational strength, but faces risks from rising debt levels and competitive pressures. Analyst sentiment is mixed with 40% buy ratings, suggesting cautious optimism amid near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
